GOLDEN, CO / ACCESSWIRE / February 15, 2022 / Panacea Life Sciences, Inc. (OTCQB:PLSH), ("Panacea" or the "Company"), a Colorado, USA-based cannabinoid company providing natural, non-habit-forming health and wellness products, announces the launch of their highest potency tincture yet, the 3300mg Cannabidiol Oral Solution. Along with their recently launched CBDA Oil Drops, the 3300mg tincture aligns with Panacea's mission to produce purposeful formulations that enhance peoples' and pets' health and wellbeing.
Panacea's 3300mg high-potency tincture is a cost effective and quality-controlled product designed specifically for those requiring higher doses of cannabidiol (CBD) to enjoy a healthy lifestyle. For years, studies have been looking into CBD's potential to help people cope with chronic pain, epilepsy, seizures, and anxiety. While dosing and efficacy remain to be determined, the growing number of clinical studies using high-dose CBD are encouraging for those suffering from many debilitating conditions.
Panacea's Chief Science Officer, James Baumgartner, Ph.D., emphasizes, "As a cannabinoid company, Panacea remains committed to research on CBD (and other cannabinoids) dosing, bioavailability, and understanding how CBD supports human and pet health. The 3300mg high potency CBD oral tincture was requested by many of our customers, and with it is an important addition to Panacea's product portfolio for those that require high doses of CBD for daily functions."
The 3300mg Cannabidiol Oral Solution product is one of the most cost-effective products on the market at just $0.03 per milligram, and at the recommended servings of 1 dropper per day from a 30mL bottle, this equates to $3 per day verses a similar product that costs almost five times this amount.
Panacea's 3300mg Cannabidiol Oral Solution tincture is made from hemp that is grown, manufactured, and third-party tested in Colorado. Panacea follows strict quality control protocols to make sure the purity and potency of all products are safe, have accurate concentrations and are effective. Because the main ingredient, CBD, is hemp-derived, there is no known risk of addiction or psychogenic effects. Furthermore, it is made with PANA Pure isolate, meaning it is pure CBD that is THC-Free*.
The launch of Panacea's new high-potency tincture offers an alternative for people searching for a natural product to support an improved quality of life. The company believes that the release of its 3300mg Cannabidiol Oral Solution is a major step in improving the quality of life for people who can benefit from this higher dosage product.
*THC-Free or THC-ND (non-detect) is defined as trace amounts <0.01% THC or 100ppm.
About Panacea Life Sciences Holdings, Inc.
Panacea Life Sciences Holdings, Inc. is a seed to sale cannabinoid manufacturer and research company that produces purposeful, natural medicine for consumers and pets. Panacea sells softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals. If you would like more information about this topic or to learn more about Panacea and its products or our land-to-brand practices, please visit www.panacealife.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the effectiveness of a high-potency CBD tincture improving the lives of people and pets, [no we should delete] You can identify forward-looking statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, risks arising from supply chain disruptions on our ability to obtain raw materials as well as similar problems with our vendors, the impact of the pandemic including new variants on the national and global economy, lack of available funding at sufficient levels to meet our working capital needs, competition from third parties; intellectual property rights of third parties; regulatory constraints, including the need for FDA approval under certain circumstances; and changes in technology and methods of marketing; as well as those risks and uncertainties described by us in our quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2021 under the heading "Risk Factors". Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.
Contact:
Nick Cavarra
[email protected]
SOURCE: Panacea Life Sciences, Inc.